In this review:
Demographic analysis of FIP1L1- PDGFRA-positive CEL in Australia
Median 3.5-year follow-up of ibrutinib for relapsed/refractory MCL
Stage I/II follicular lymphoma outcomes in the PET-CT staging era
Weekly carfilzomib/lenalidomide/dexamethasone in relapsed/refractory MM
Chemotherapy and venetoclax in fit, elderly AML
MRD negativity with venetoclax + rituximab in relapsed/refractory CLL
Ibrutinib impairs cytotoxic T-cell responses
High early treatment failure rates in DLBCL
Residual perfusion defects in acute PE treated with rivaroxaban vs. warfarin
Real-world DOAC experience in Australia
Please login below to download this issue (PDF)